Tallarna and ABB Strengthen Strategic Partnership With Investment Deal
22.11.2022 14:00:00 EET | Business Wire | Press release
Tallarna, an award-winning climate tech company for the built environment, today announced that it has closed a strategic partnership and minority investment deal with ABB, a technology leader in electrification and automation. This signals a joint commitment to a software-led, risk-managed approach to accelerate net zero.
ABB’s solutions connect engineering know-how and software to optimise how things are manufactured, moved, powered, and operated. Building on more than 130 years of excellence, the company's expertise will be indispensable for the next stage of Tallarna’s growth.
Since launching four years ago, Tallarna has built a talented and loyal team, and has experienced wide-scale traction across the real estate sector – encompassing social housing providers, energy infrastructure developers, and green lenders. With ABB’s backing, the company’s scope will be extended to Energy Service Companies (ESCOs) serving commercial and industrial organisations.
Tallarna’s AI platform, KESTREL, makes decarbonisation projects a reality by aligning what can be achieved from an engineering perspective with what can be insured and funded. By finding the commonality between decision makers, the company opens the door to a new era of scalability. Tallarna’s software is integrated with the related underwriting processes of AmTrust Financial Services, a global specialty property and casualty insurer, who is also an existing investor. Together, the companies have created a unique Energy Savings Insurance product which enables customers to access project investors integrated into Tallarna’s platform.
As the climate and energy crisis grows, decision makers need the right tools to lower their emissions and operating costs. ABB’s deep knowledge of equipment performance and innovative electrification technology will enhance Tallarna’s existing capabilities. Coupling ABB products with performance insurance will give customers the confidence to action their sustainability journey.
“Never before has there been such a need for clear insights into decarbonisation possibilities and how to deliver them. Cross-industry collaboration is key to ensuring a sustainable future for all. As such, we are delighted to be working more closely with the Tallarna team and to support their launch in the ESCO market,” Giuseppe Casagrande, Global Digital Leader at ABB Electrification, Smart Power Division.
“As a company, our mission is to empower sustainability in all its forms – environmental, economic, and social. ABB shares this perspective, and we are excited to work with them on addressing the awareness, confidence, and execution gap facing customers,” Tim Meanock, CEO at Tallarna.
ABB’s investment and partnership will guide Tallarna in growing the market - taking decarbonisation to new heights for commercial, industrial, and energy infrastructure providers.
ESCO customers will benefit in 4 key ways:
-
Lower the barrier to entry for decarbonisation projects
Tallarna understands customers’ decarbonisation options using minimal data and, initially, without the need for connected devices. This capability will be augmented with ABB’s knowledge of innovative energy optimisation solutions in industrial settings.
-
Point a route to scale for customer projects
KESTREL translates engineering challenges into risk metrics and is used to underwrite and distribute Energy Savings Insurance. By adding ABB’s insights to this modelling, the companies will further mitigate risk while lowering costs and carbon emissions. Removing the performance risk from ESCOs and building owners encourages greater project scope and facilitates a service model, driving a route to scale.
-
Enable the market to move faster by overcoming barriers to execution
Guaranteed energy outputs can be financed, with the realised bill savings repaying the project costs. Not only does this deliver new funding sources for developers, but it creates financial assets for Tallarna’s panel of project investors. This provides a key mechanism for execution.
-
Ensure security of technology supply and performance
Tallarna can specify suitable technology products at the project exploration stage. These include offerings from a range of providers, including ABB. Technology is pre-validated for insurance and finance terms, and can be onboarded to provide security of supply, performance, and pricing.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221122005392/en/
Contact information
Michelle Taute
Senior Strategic Sustainability Lead
press@tallarna.com
+44 7771786102
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Plus Expands Relationship with SS&C to Support Cross-Border Operations in APAC3.8.2026 04:00:00 EEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that First Plus Asset Management (FPAM), a multi-asset investment management firm, has selected SS&C to provide cross-border operations support across Asia. SS&C will service First Plus across the full investment lifecycle, delivering a scalable, integrated solution supporting transfer agency, order management and execution and investment accounting. FPAM will utilize SS&C to service its growing cross-border operating model and support around $200 million in assets under management*. “As First Plus has expanded, managing our operations has become increasingly complex,” said Jeb Li, Co-Founder and CEO at First Plus. “SS&C’s global footprint and integrated offerings enable us to easily optimize our workflows, so we can focus on scaling quickly and securely while continuing to deliver risk-adjusted returns and best-in-class client service.” The engagement highlights the breadth and scalability of SS&C’s global service model.
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 11:01:00 EEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
